EXTON, Pa., July 07, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ:FCSC) today announced that David Pernock, Chairman and Chief Executive Officer of Fibrocell, will present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference at 1:30 pm ET on Wednesday, July 13 in New York City. Prior to his presentation, Mr. Pernock will participate in a panel discussion on gene therapy at 12:15 pm ET.
Fibrocell’s presentation will be posted under the investor relations section of the company’s website at www.fibrocell.com/investors/events and archived for 30 days.
Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin, connective tissue and joints. Fibrocell’s most advanced gene-therapy product candidate, FCX-007, is entering a Phase I/II trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is in pre-clinical development of FCX-013, its gene-therapy product candidate for the treatment of linear scleroderma. In addition, Fibrocell has a third gene therapy program in the research phase for the treatment of arthritis and related conditions. Fibrocell’s gene therapy portfolio is being developed in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology. For more information, visit www.fibrocell.com or follow us on Twitter at @Fibrocell.
Fibrocell, the Fibrocell logo and Fibrocell Science are trademarks of Fibrocell Science, Inc. and/or its affiliates. All other names may be trademarks of their respective owners.
Investor Relations Contact: John Woolford Westwicke Partners 443.213.0506 firstname.lastname@example.org
Source:Fibrocell Science, Inc.